Palvella Therapeutics, Inc. $PVLA Shares Sold by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lowered its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 57.7% during the fourth quarter, Holdings Channel reports. The fund owned 40,259 shares of the company’s stock after selling 55,000 shares during the quarter. Palvella Therapeutics makes up 0.3% of Blue Owl Capital Holdings LP’s holdings, making the stock its 25th largest holding. Blue Owl Capital Holdings LP’s holdings in Palvella Therapeutics were worth $4,214,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PVLA. Archer Investment Corp purchased a new position in Palvella Therapeutics during the third quarter valued at approximately $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the 3rd quarter worth approximately $36,000. JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Palvella Therapeutics during the second quarter valued at $85,000. Finally, BNP Paribas Financial Markets acquired a new stake in Palvella Therapeutics during the second quarter valued at $104,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

PVLA opened at $113.99 on Monday. The firm has a market capitalization of $1.63 billion, a PE ratio of -27.34 and a beta of -0.13. Palvella Therapeutics, Inc. has a twelve month low of $20.20 and a twelve month high of $151.18. The firm’s 50-day moving average price is $121.93 and its 200 day moving average price is $105.65.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Elaine J. Heron bought 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on PVLA. Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Finally, BTIG Research raised their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Palvella Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $199.53.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.